Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Antiinflammatory properties of HDL.

Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM.

Circ Res. 2004 Oct 15;95(8):764-72. Review.

2.

Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.

Ribas V, Sánchez-Quesada JL, Antón R, Camacho M, Julve J, Escolà-Gil JC, Vila L, Ordóñez-Llanos J, Blanco-Vaca F.

Circ Res. 2004 Oct 15;95(8):789-97. Epub 2004 Sep 23.

3.

Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation.

Moore RE, Navab M, Millar JS, Zimetti F, Hama S, Rothblat GH, Rader DJ.

Circ Res. 2005 Oct 14;97(8):763-71. Epub 2005 Sep 8.

4.

Inhibition of endothelial cell adhesion molecule expression by high density lipoproteins.

Barter PJ.

Clin Exp Pharmacol Physiol. 1997 Mar-Apr;24(3-4):286-7.

PMID:
9131299
5.

Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles.

Castellani LW, Navab M, Van Lenten BJ, Hedrick CC, Hama SY, Goto AM, Fogelman AM, Lusis AJ.

J Clin Invest. 1997 Jul 15;100(2):464-74.

6.

The role of oxidized HDL in monocyte/macrophage functions in the pathogenesis of atherosclerosis in Rhesus monkeys.

Sharma N, Desigan B, Ghosh S, Sanyal SN, Ganguly NK, Majumdar S.

Scand J Clin Lab Invest. 1999 May;59(3):215-25.

PMID:
10400166
7.
9.

Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence.

Nofer JR, Walter M, Assmann G.

Expert Rev Cardiovasc Ther. 2005 Nov;3(6):1071-86. Review.

PMID:
16292998
10.

Serum, but not monocyte macrophage foam cells derived from low HDL-C subjects, displays reduced cholesterol efflux capacity.

Nakanishi S, Vikstedt R, Söderlund S, Lee-Rueckert M, Hiukka A, Ehnholm C, Muilu M, Metso J, Naukkarinen J, Palotie L, Kovanen PT, Jauhiainen M, Taskinen MR.

J Lipid Res. 2009 Feb;50(2):183-92. doi: 10.1194/jlr.M800196-JLR200. Epub 2008 Sep 11.

11.

Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides.

Yu R, Yekta B, Vakili L, Gharavi N, Navab M, Marelli D, Ardehali A.

Curr Atheroscler Rep. 2008 Apr;10(2):171-6. Review.

PMID:
18417073
12.

High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease.

Rohrer L, Hersberger M, von Eckardstein A.

Curr Opin Lipidol. 2004 Jun;15(3):269-78. Review.

PMID:
15166782
13.

Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.

Vaziri ND.

J Ren Nutr. 2010 Sep;20(5 Suppl):S35-43. doi: 10.1053/j.jrn.2010.05.010. Review.

PMID:
20797569
14.

High-density lipoproteins as therapeutic targets.

Nicholls SJ, Rye KA, Barter PJ.

Curr Opin Lipidol. 2005 Jun;16(3):345-9. Review.

PMID:
15891397
15.

Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells.

Negre-Salvayre A, Dousset N, Ferretti G, Bacchetti T, Curatola G, Salvayre R.

Free Radic Biol Med. 2006 Oct 1;41(7):1031-40. Epub 2006 Jul 12. Review.

PMID:
16962927
16.

Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes.

Patel S, Drew BG, Nakhla S, Duffy SJ, Murphy AJ, Barter PJ, Rye KA, Chin-Dusting J, Hoang A, Sviridov D, Celermajer DS, Kingwell BA.

J Am Coll Cardiol. 2009 Mar 17;53(11):962-71. doi: 10.1016/j.jacc.2008.12.008.

17.

New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease.

Barter PJ, Puranik R, Rye KA.

Curr Cardiol Rep. 2007 Nov;9(6):493-8. Review.

PMID:
17999875
18.

Paraoxonase-1 reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl glycerophosphorylcholine.

Ahmed Z, Babaei S, Maguire GF, Draganov D, Kuksis A, La Du BN, Connelly PW.

Cardiovasc Res. 2003 Jan;57(1):225-31.

19.

New strategies in managing and preventing atherosclerosis: focus on HDL.

Price MJ, Shah PK.

Rev Cardiovasc Med. 2002 Summer;3(3):129-37. Review.

PMID:
12439437
20.

Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins.

Tall AR.

J Intern Med. 2008 Mar;263(3):256-73. doi: 10.1111/j.1365-2796.2007.01898.x. Review.

Items per page

Supplemental Content

Write to the Help Desk